Datapoint: J&J’s Ponvory to Enter MS Market

The FDA last week approved Johnson & Johnson’s Janssen unit’s Ponvory for the treatment of relapsing forms of multiple sclerosis (MS). The SIP modulator will face off against Novartis stalwarts Gilenya and Mayzent. Another recent entry into the MS space is Bristol Myers Squibb’s Zeposia, which won FDA approval in March 2020. For the treatment of MS under the pharmacy benefit, Zeposia currently holds preferred formulary placement for 5% of covered lives, growing to 22% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/17/21

0

0

0 Comments

0

0

• Datapoint